Jeremy S Disch
Overview
Explore the profile of Jeremy S Disch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ackloo S, Li F, Szewczyk M, Seitova A, Loppnau P, Zeng H, et al.
J Med Chem
. 2024 Nov;
68(2):1092-1112.
PMID: 39495097
Target class-focused drug discovery has a strong track record in pharmaceutical research, yet public domain data indicate that many members of protein families remain unliganded. Here we present a systematic...
2.
Ramos A, Goedken E, Frank K, Argiriadi M, Bazzaz S, Bian Z, et al.
J Med Chem
. 2024 Apr;
67(8):6456-6494.
PMID: 38574366
Dysregulation of IL17A drives numerous inflammatory and autoimmune disorders with inhibition of IL17A using antibodies proven as an effective treatment. Oral anti-IL17 therapies are an attractive alternative option, and several...
3.
Li A, Kimani S, Wilson B, Noureldin M, Gonzalez-Alvarez H, Mamai A, et al.
J Med Chem
. 2023 Mar;
66(7):5041-5060.
PMID: 36948210
DCAF1 is a substrate receptor of two distinct E3 ligases (CRL4 and EDVP), plays a critical physiological role in protein degradation, and is considered a drug target for various cancers....
4.
Collie G, Barlind L, Bazzaz S, Borjesson U, Dale I, Disch J, et al.
Bioorg Med Chem Lett
. 2022 Aug;
75:128948.
PMID: 35987508
The c-MET receptor tyrosine kinase has received considerable attention as a cancer drug target yet there remains a need for inhibitors which are selective for c-MET and able to target...
5.
Disch J, Duffy J, Lee E, Gikunju D, Chan B, Levin B, et al.
J Med Chem
. 2021 Apr;
64(8):5049-5066.
PMID: 33844532
Bispecific degraders (PROTACs) of ERα are expected to be advantageous over current inhibitors of ERα signaling (aromatase inhibitors/SERMs/SERDs) used to treat ER+ breast cancer. Information from DNA-encoded chemical library (DECL)...
6.
Nissink J, Bazzaz S, Blackett C, Clark M, Collingwood O, Disch J, et al.
J Med Chem
. 2021 Mar;
64(6):3165-3184.
PMID: 33683117
Mer is a member of the TAM (Tyro3, Axl, Mer) kinase family that has been associated with cancer progression, metastasis, and drug resistance. Their essential function in immune homeostasis has...
7.
Dai H, Case A, Riera T, Considine T, Lee J, Hamuro Y, et al.
Nat Commun
. 2015 Jul;
6:7645.
PMID: 26134520
SIRT1, the founding member of the mammalian family of seven NAD(+)-dependent sirtuins, is composed of 747 amino acids forming a catalytic domain and extended N- and C-terminal regions. We report...
8.
Hubbard B, Loh C, Gomes A, Li J, Lu Q, Doyle T, et al.
Cell Cycle
. 2013 Jul;
12(14):2233-40.
PMID: 23892437
SIRT1 is an NAD (+) -dependent deacetylase that counteracts multiple disease states associated with aging and may underlie some of the health benefits of calorie restriction. Understanding how SIRT1 is...
9.
Disch J, Evindar G, Chiu C, Blum C, Dai H, Jin L, et al.
J Med Chem
. 2013 Apr;
56(9):3666-79.
PMID: 23570514
The sirtuins SIRT1, SIRT2, and SIRT3 are NAD(+) dependent deacetylases that are considered potential targets for metabolic, inflammatory, oncologic, and neurodegenerative disorders. Encoded library technology (ELT) was used to affinity...
10.
Hubbard B, Gomes A, Dai H, Li J, Case A, Considine T, et al.
Science
. 2013 Mar;
339(6124):1216-9.
PMID: 23471411
A molecule that treats multiple age-related diseases would have a major impact on global health and economics. The SIRT1 deacetylase has drawn attention in this regard as a target for...